Current status of cardiovascular gene therapy

Molecular Therapy

Volumn 15, Issue 7, 2007, Pages 1233-1247

  Rissanen, Tuomas T ^a   Ylä Herttuala, Seppo ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENIC FACTOR; ANTISENSE OLIGONUCLEOTIDE; BACULOVIRUS VECTOR; EDIFOLIGIDE; ETOPOSIDE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 4; HERPESVIRUS VECTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISIS 301012; LENTIVIRUS VECTOR; LIPOSOME; NAKED DNA; PARVOVIRUS VECTOR; PLACEBO; PLACENTAL GROWTH FACTOR; PLASMID DNA; PLATELET DERIVED GROWTH FACTOR; POLYMER; RECOMBINANT VASCULOTROPIN; RETROVIRUS VECTOR; SCATTER FACTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN C; VASCULOTROPIN D;

ANGIOGENESIS; BLOOD VESSEL GRAFT; BYPASS SURGERY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG HALF LIFE; EDEMA; ELECTROPORATION; GENE DELIVERY SYSTEM; GENE TARGETING; GENE TECHNOLOGY; GENE THERAPY; GENE TRANSFER; GRAFT FAILURE; GRAFT PATENCY; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INJECTION SITE ERYTHEMA; LIMB ISCHEMIA; META ANALYSIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PATIENT SELECTION; PERIPHERAL VASCULAR DISEASE; RESTENOSIS; REVIEW; SYSTEMATIC REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; ULTRASOUND; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; ELECTROPHYSIOLOGY; GENE THERAPY; GENETIC VECTORS; HUMANS; TRANSGENES;

ADENO-ASSOCIATED VIRUS;

EID: 34250772826     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300175     Document Type: Review

References (200)

1. Yla-Herttuala, S and Martin, JF (2000). Cardiovascular gene therapy. Lancet 355: 213-222.
2. Svet-Moldavsky, GJ and Chimishkyan, KL (1977). Tumour angiogenesis factor for revascularisation in ischaemia and myocardial infarction. Lancet 1: 913.
3. Yanagisawa-Miwa, A, Uchida, Y, Nakamura, F, Tomaru, T, Kido, H, Kamijo, T et al. (1992). Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 257: 1401-1403.
4. Henry, TD, Annex, BH, McKendall, GR, Azrin, MA, Lopez, JJ, Giordano, FJ et al. (2003). The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 107: 1359-1365.
5. Lederman, RJ, Mendelsohn, FO, Anderson, RD, Saucedo, JF, Tenaglia, AN, Hermiller, JB et al. (2002). Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): A randomised trial. Lancet 359: 2053-2058.
6. Simons, M, Annex, BH, Laham, RJ, Kleiman, N, Henry, T, Dauerman, H et al. (2002). Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial. Circulation 105: 788-793.
7. Lazarous, DF, Shou, M, Stiber, JA, Hodge, E, Thirumurti, V, Goncalves, L et al. (1999). Adenoviral-mediated gene transfer induces sustained pericardiall VEGF expression in dogs: Effect on myocardial angiogenesis. Cardiovasc Res 44: 294-302.
8. Yla-Herttuala, S and Alitalo, K (2003). Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 9: 694-701.
9. Tsurumi, Y, Takeshita, S, Chen, D, Kearney, M, Rossow, ST, Passeri, J et al. (1996). Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 94: 3281-3290.
10. Isner, JM, Baumgartner, I, Rauh, G, Schainfeld, R, Blair, R, Manor, O et al. (1998). Treatment of thromboangitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: Preliminary clinical results. J Vasc Surg 28: 964-973.
11. Baumgartner, I, Pleczek, A, Manor, O, Blair, R, Keamey, M, Walsh, K et al. (1998). Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97: 1114-1123.
12. Vale, PR, Losordo, DW, Milliken, CE, McDonald, MC, Gravelin, LM, Curry, CM et al. (2001). Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 103: 2138-2143.
13. Fortuin, FD, Vale, P, Losordo, DW, Symes, J, DeLaria, GA, Tyner, JJ et al. (2003). One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients. Am J Cardiol 92: 436-439.
14. Makinen, K, Manninen, H, Hedman, M, Matsi, P, Mussalo, H, Alhava, E et al. (2002). Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: A randomized, placebo-controlled, double-blinded phase II study. Mol Ther 6: 127-133.
15. Hedman, M, Hartikainen, J, Syvanne, M, Stjernvall, J, Hedman, A, Kivela, A et al. (2003). Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: Phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 107: 2677-2683.
16. Kastrup, J, Jorgensen, E, Ruck, A, Tagil, K, Glogar, D, Ruzyllo, W et al. (2005). Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: The Euroinject One trial. J Am Coll Cordiol 45: 982-988.
17. Kusumanto, YH, Weel, VV, Mulder, NH, Smit, AJ, Dungen, JJ, Hooymans, JM et al. (2006). Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: A double-blind randomized trial. Hum Gene Ther 17: 683-691.
18. Corautus Genetics (2006). Corautus announces termination of patient enrollment in GENASIS severe angina clinical trial. Corautus Genetics .
19. Laitinen, M, Pakkanen, T, Donetti, E, Baetta R, Luoma, J, Lehtolainen, P et al. (1997). Gene transfer into the carotid artery using an adventitial collar: Comparison of the effectiveness of the plasmid-liposome complexes, retroviruses, pseudotyped retroviruses, and adenoviruses. Hum Gene Ther 8: 1645-1650.
20. Wright, MJ, Wightman, LM, Lilley, C, de Alwis, M, Hart, SL, Miller, A et al. (2001). In vivo myocardial gene transfer: Optimization, evaluation and direct comparison of gene transfer vectors. Basic Res Cardiol 96: 227-236.
21. Rutanen, J, Rissanen, TT, Markkanen, JE, Gruchala, M, Silvennoinen, P, Kivela, A et al. (2004). Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation 109: 1029-1035.
22. Hao, X, Mansson-Broberg, A, Grinnemo, KH, Siddiqui, AJ, Dellgren, G, Brodin, LA et al. (2007). Myocardial angiogenesis after plasmid or adenoviral VEGF-A(165) gene transfer in rat myocardial infarction model. Cardiovasc Res 73: 481-487.
23. Mathiesen, I (1999). Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 6: 508-514.
24. Yamashita, Y, Shimada, M, Tachibana, K, Harimoto, N, Tsujita, E, Shirabe, K et al. (2002). In vivo gene transfer into muscle via electro-sonoporation. Hum Gene Ther 13: 2079-2094.
25. Wright, MJ, Rosenthal, E, Stewart, L, Wightman, LM, Miller, AD, Latchman, DS et al. (1998). β-Galactosidase staining following intracoronary infusion of cationic liposomes in the in vivo rabbit heart is produced by microinfarction rather than effective gene transfer: A cautionary tale. Gene Ther 5: 301-308.
26. McMahon, JM, Wells, KE, Bamfo, JE, Cartwright MA and Wells, DJ (1998). Inflammatory responses following direct injection of plasmid DNA into skeletal muscle. Gene Ther 5: 1283-1290.
27. Kankkonen, HM, Vahakangas, E, Marr, RA, Pakkanen, T, Laurema, A, Leppanen, P et al. (2004). Long-term lowering of plasma cholesterol levels in LDL-receptor-deficient WHHL rabbits by gene therapy. Mol Ther 9: 548-556.
28. Dishart KL, Denby, L, George, SJ, Nicklin, SA, Yendluri, S, Tuerk, MJ et al. (2003). Third-generation lentivirus vectors efficiently transduce and phenotypically modify vascular cells: Implications for gene therapy. J Mol Cell Cardiol 35: 739-748.
29. Kankkonen, HM, Turunen, MP Hiltunen, MO, Lehtolainen, P, Koponen, J, Leppanen, P et al. (2004). Feline immunodeficiency virus and retrovirus-mediated adventitlal ex vivo gene transfer to rabbit carotid artery using autologous vascular smooth muscle cells. J Mol Cell Cardiol 36: 333-341.
30. Cefai, D, Simeoni, E, Ludunge, KM, Driscoll, R, von Segesser, LK, Kappenberger, L et al. (2005). Multiply attenuated, self-inactivating lentiviral vectors efficiently transduce human coronary artery cells in vitro and rat arteries in vivo. J Mol Cell Cardiol 38: 333-344.
31. Masaki, I, Yonemitsu, Y, Komori, K, Ueno, H, Nakashima, Y, Nakagawa, K et al. (2001). Recombinant Sendai virus-mediated gen-transfer to vasculature: A new class of efficient gene transfer vector to the vascular system. FASEB J 15: 1294-1296.
32. Coffin, RS, Howard, MK, Cumming, DV, Dollery, CM, McEwan, J, Yellon, DM et al. (1996). Gene delivery to the heart in vivo and to cardiac myocytes and vascular smooth muscle cells in vitro using herpes virus vectors. Gene Ther 3: 560-566.
33. Airenne, KJ, Hiltunen, MO, Turunen, MP, Turunen, AM, Laitinen, OH, Kulomaa, MS et al. (2000). Baculovirus-mediated periadventitial gene transfer to rabbit carotid artery. Gene Ther 7: 1499-1504.
34. Alexander, JH, Hafley G, Harrington, RA, Peterson, ED, Ferguson, TB Jr., Lorenz, TJ et al. (2005). Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure followAng coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 294: 2446-2454.
35. Conte, MS, Bandyk, DF, Clowes, AW, Moneta, GL, Seety L, Lorenz, TJ et al. (2006). Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 43: 742-751.
36. Fichou, Y and Ferec, C (2006). The potential of oligoncleotides for therapeutic applications. Trends Biotechnol 24: 563-570.
37. Poliakova, L, Kovesdi, I, Wang, X, Capogrossi, MC and Talan, M (1999). Vascular permeability effect of adenovirus-mediated vascular endothelial growth factor gene transfer to the rabbit and rat skeletal muscle. J Thorac Cardiovasc Surg, 118: 339-347.
38. Rissanen, TT, Markkanen, JE, Gruchala, M, Heikura, T, Puranen, A, Kettunen, MI et al. (2003). VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res 92: 1098-1106.
39. Zoltick, PW, Chirmule, N, Schnell, MA, Gao, GP, Hughes, JV and Wilson, JM (2001). Biology of E1-deleted adenovirus vectors in nonhuman primate muscle. J Virol 75: 5222-5229.
40. Rissanen, TT, Korpisalo, P, Markkanen, JE, Liimatainen, T, Orden, MR, Kholova, I et al. (2005). Blood flow remodels growing vasculature during vascular endothelial growth factor gene therapy and determines between capillary arterialization and sprouting angiogenesis. Circulation 112: 3937-3946.
41. Wen, S, Graf, S, Massey, PG and Dichek, DA (2004). Improved vascular gene transfer with a helper-dependent adenoviral vector. Circulation 110: 1484-1491.
42. Nalbantoglu, J, Pari, G, Karpati, G and Holland, PC (1999). Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells. Hum Gene Ther 10: 1009-1019.
43. Vajanto, I, Rissanen, TT, Rutanen, J, Hiltunen, MO, Tuomisto, TT, Arve, K et al. (2002). Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ. J Gene Med 4: 371-380.
44. Hiltunen, MO, Laitinen, M, Turunen, MP, Jeltsch, M, Hartikainen, J, Rissanen, TT et al. (2000). Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation 102: 2262-2268.
45. Laitinen, M, Mäkinen, K, Manninen, H, Matsi, P, Kossila, M, Agrawal, RS et al. (1998). Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia. Hum Gene Ther 9:1481-1486.
46. Rissanen, TT, Markkanen, JE, Arve, K, Rutanen, J, Kettunen, MI, Vajanto, J et al. (2003). Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model. FASEB J 17: 100-102.
47. Thirion, C, Lochmuller, H, Ruzsics, Z, Boelhauve, M, Konig, C, Thedieck, C et al. (2006). Adenovirus vectors based on human adenovirus type 19a have high potential for human muscle-directed gene therapy. Hum Gene Ther 17: 193-205.
48. Nicklin, SA, White, SJ, Nicol, CG, Von Seggem, DJ and Baker, AH (2004). In vitro and in vivo characterisation of endothelial cell selective adenoviral vectors. J Gene Med 6: 300-308.
49. Raper, SE, Chirmule, N, Lee, FS, Wivel, NA, Bagg, A, Gao, GP et al. (2003). Fatal systemic inflammatory response syndrome in a omithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80: 148-158.
50. Gruchala, M, Bhardwaj, S, Pajusola, K, Roy, H, Rissanen, TT, Kokina, I et al. (2004). Gene transfer into rabbit arteries with adeno-associated virus and adenovirus vectors. J Gene Med 6: 545-554.
51. Su, H, Huang, Y, Takagawa, J, Barcena, A, Arakawa-Hoyt, J, Ye, J et al. (2006). AAV serotype-1 mediates early onset of gene expression in mouse hearts and results in better therapeutic effect. Gene Ther 13: 1495-1502.
52. Schnepp, BC, Clark, KR, Klemanski, DL, Pacak, CA and Johnson, PR (2003). Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol 77: 3495-3504.
53. Wang, Z, Zhu, T, Qiao, C, Zhou, L, Wang, B, Zhang, J et al. (2005). Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 23: 321-328.
54. Kawamoto, S, Shi, Q, Nitta, Y, Miyazaki, J and Allen, MD (2005). Widespread and early myocardial gene expression by adeno-associated virus vector type 6 with a beta-actin hybrid promoter. Mol Ther 11: 980-985.
55. Pacak, CA, Mah, CS, Thattaliyath, BD, Conlon, TJ, Lewis, MA, Cloutier, DE et al. (2006). Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 99 e3-e9.
56. Work, LM, Buning, H, Hunt E, Nicklin, SA, Denby, L, Britton, N et al. (2006). Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses. Mol Ther 13: 683-693.
57. Jiang, H, Pierce, GF, Ozelo, MC, de Paula, EV, Vargas, JA, Smith, P et al. (2006). Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther 14:452-455.
58. Aikawa, R, Huggins, GS and Snyder, RO (2002). Cardiomyocyte-specific gene expression following recombinant adeno-associated viral vector transduction. J Biol Chem 277:18979-18985.
59. Su, H, Joho, S, Huang, Y, Barcena, A, Arakawa-Hoyt, J, Grossman, W et al. (2004). Adeno-associated viral vector delivers cardiac-specific and hypoxia-inducible VEGF expression in ischemic mouse hearts. Proc Natl Acad Sci USA 101: 16280-16285.
60. Varenne, O, Pislaru, S, Gillijns, H, Van Pelt, N, Gerard, RD, Zoldhelyi, P et al. (1998). Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation 98: 919-926.
61. Walter, DH, Cejna, M, Diaz-Sandoval, L, Willis, S, Kirkwood, L, Stratford, PW et al. (2004). Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: An alternative strategy for inhibition of restenosis. Circulation 110: 36-45.
62. Sharif, F, Hynes, SO, McMahon, J, Cooney, R, Conroy, S, Dockery, P et al. (2006). Gene eluting stents: Comparison of adenoviral and adeno-associated viral gene delivery to the blood vessel wall in vivo. Hum Gene Ther 17: 741-750.
63. Turunen, P, Puhakka, HL, Heikura, T, Romppanen, E, Inkala, M, Leppanen, O et al. (2006). Extracellular superoxide dismutase with vaccinia virus anti-inflammatory protein 35K or tissue inhibitor of metalloproteinase-1: Combination gene therapy in the treatment of vein graft stenosis in rabbits. Hum Gene Ther 17: 405-414.
64. Wright, MJ, Wightman, LM, Latchman, DS and Marber, MS (2001). In vivo myocardial gene transfer: Optimization and evaluation of intracoronary gene delivery in vivo. Gene Ther 8: 1833-1839.
65. Lee, LY, Patel, SR, Hackett, NR, Mack, CA, Polce, DR, El-Sawy, T et al. (2000). Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann Thorac Surg 69: 14-23.
66. Springer, ML, Chen, AS, Kraft, PE, Bednarski, M and Blau, HM (1998). VEGF gene delivery to muscle: Potential role for vasculogenesis in adults. Mol Cell 12: 549-558.
67. Lee, RJ, Springer, ML, Blanco-Bose, WE, Shaw, R, Ursell, PC and Blau, HM (2000). VEGF gene delivery to myocardium: Deleterious effects of unregulated expression. Circulation 102: 898-901.
68. Pakkanen, TM, Laitinen, M, Hippelainen, M, Kallionpaa, H, Lehtolainen, P, Leppanen, P et al. (1999). Enhanced plasma cholesterol lowering effect of retrovirus-mediated LDL receptor gene transfer to WHHL rabbit liver after improved surgical technique and stimulation of hepatocyte proliferation by combined partial liver resection and thymidine kinase ganciclovir treatment Gene Ther 6: 34-41.
69. Yla-Hertthuala, S, Rissanen, TT, Vajanto, I and Hartikainen, J (2006). Vascular endothelial growth factors: Biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 49: 1015-1026.
70. Hiltunen, MO, Ruuskanen, M, Huuskonen, J, Mahonen, AJ, Ahonen, M, Rutanen, J et al. (2003). Adenovirus-mediated VEGF-A gene transfer induces bone formation in vivo. FASEB J 17: 1147-1149.
71. Zacchigna, S, Papa, G, Antonini, A, Novati, F, Moimas, S, Carrer, A et al. (2005). Improved survival of ischemic cutaneous and musculocutaneous flaps after vascular endothelial growth factor gene transfer using adeno-associated virus vectors. Am J Pathol 167 981-991.
72. Shen, F, Su, H, Fan, Y, Chen, Y, Zhu, Y, Liu, W et al. (2006). Adeno-associated viral-vector-mediated hypoxia-inducible vascular endothelial growth factor gene expression attenuates ischemic brain injury after focal cerebral ischemia in mice. Stroke 37: 2601-2606.
73. Mack, CA, Patel, SR, Schwarz, EA, Zanzonico, P, Hahn, RT, Ilercil, A et al. (1998). Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 115: 168-176.
74. Gowdak, LH, Poliakova, L, Wang, X, Kovesdi, I, Fishbein, KW, Zacheo, A et al. (2000). Adenovirus-mediated VEGF(l21) gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia. Circulation 102 565-571.
75. Pettersson, A, Nagy, JA, Brown, LF, Sundberg, C, Morgan, E, Jungles, S et al. (2000). Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest 80: 99-115.
76. Springer, ML, Ozawa, CR, Banfi, A, Kraft, PE, Ip TK, Brazelton, TR et al. (2003). Localized arteriole formation directly adjacent to the site of VEGF-Induced angiogenesis in muscle. Mol Ther 7: 441-449.
77. Arsic, N, Zentilin, L, Zacchigna, S, Santoro, D, Stanta, G, Salvi, A et al. (2003). Induction of functional neovascularization by combined VEGF and angiopoietin-1 gene transfer using AAV vectors. Mol Ther 7: 450-459.
78. Parsons-Wingerter, P, Chandrasekharan, UM, McKay, TL, Radhakrishnan, K, DiCorleto, PE, Albarran, B et al. (2006). A VEGF165-induced phenotypic switch from increased vessel density to increased vessel diameter and increased endothelial NOS activity. Microvasc Res 72: 91-100.
79. Greve, JM, Chico, TJ, Goldman, H, Bunting, S, Peale, FV Jr., Daugherty, A et al. (2006). Magnetic resonance angiography reveals therapeutic enlargement of collateral vessels induced by VEGF in a murine model of peripheral arterial disease. J Magn Reson Imaging 24: 1124-1132.
80. Eitenmuller, I, Volger, O, Kluge, A, Troidl, K, Barancik, M, Cai, WJ et al. (2006). The range of adaptation by collateral vessels after femoral artery occlusion. Circ Res 99: 656-662.
81. Zentilin, L, Tafuro, S, Zacchigna, S, Arsic, N, Pattarini, L, Sinigaglia, M et al. (2006). Bone marrow mononuclear cells are recruited to the sites of VEGF-Induced neovascularization but are not incorporated into the newly formed vessels. Blood 107: 3546-3554.
82. Vincent, KA, Shyu, KG, Luo, Y, Magner, M, Tio, RA, Jiang, C et al. (2000). Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1α/VP16 hybrid transcription factor. Circulation 102: 2255-2261.
83. Dal, Q, Huang, J, Klitzman, B, Dong, C, Goldschmidt-Clermont, PJ, March, KL et al. (2004). Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmd DINA induces therapeutic angiogenesis in rabbits with hindlimb ischemia. Circulation 110: 2467-2475.
84. Whitlock, PR, Hackett, NR, Leopold, PL, Rosengart, TK and Crystal, RG (2004). Adenavirus-mediated transfer of a minigene expressing multiple isoforms of VEGF is more effective at inducing angiogenesis than comparable vectors expressing individual VEGF cDNAs. Mol Ther 9 67-75.
85. Zheng, Y, Murakami, M, Takahashi, H, Yamauchi, M, Kiba, A, Yamaguchi, S et al. (2006). Chimeric VEGF-E(NZ7)/PIGF promotes angiogenesis via VEGFR-2 without significant enhancement of vascular permeability and inflammation. Arterioscler Thromb Vasc Biol 26: 2019-2026.
86. Dor, Y, Djonov, V, Abramovitch, R, Itin, A, Fishman, GI, Carmeliet, P et al (2002). Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J 21: 1939-1947.
87. Joukov, V, Pajusola, K, Kaipainen, A, Chilov, D, Lahtinen, I, Kukk, E et al. (1996). A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15: 290-298.
88. Saaristo, A, Tammela, T, Timonen, J, Yla-Herttuala, S, Tukiainen, E, Asko-Seljavaara, S et al. (2004). Vascular endothelial growth factor-C gene therapy restores lymphatic flow across incision wounds. FASEB J 18: 1707-1709.
89. Ogawa, S, Oku, A, Sawano, A, Yamaguchi, S, Yazaki, Y and Shibuya, M (1998). A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/FIk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 273: 31273-31282.
90. Odorisio, T, Schietroma, C, Zaccaria, ML, Cianfarani, F, Tiveron, C, Tatangelo, L et al. (2002). Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J Cell Sci 115: 2559-2567.
91. Silvestre, JS, Tamarat, R, Ebrahimian, TG, Le-Roux, A, Clergue, M, Emmanuel, F et al. (2003). Vascular endothelial growth factor-B promotes in vivo angiogenesis. Circ Res 93: 114-123.
92. Roy, H, Bhardwaj, S, Babu, M, Jauhiainen, S, Herzig, KH, Bellu, AR et al. (2005). Adenovirus-mediated gene transfer of placental growth factor to perivascular tissue induces angiogenesis via upregulation of the expression of endogenous vascular endothelial growth factor-A. Hum Gene Ther 16: 1422-1428.
93. Miller, DL, Ortega, S, Bashayan, O, Basch, R and Basilico, C (2000). Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice. Mol Cell Biol 20: 2260-2268.
94. Muhlhauser, J, Pili, R, Merrill, MJ, Maeda, H, Passaniti, A, Crystal, RG et al. (1995). In vivo angiogenesis induced by recombinant adenovirus vectors coding either for secreted or nonsecreted forms of acidic fibroblast growth factor. Hum Gene Ther 6: 1457-1465.
95. Ueno, H, Li, JJ, Masuda, S, Qi, Z, Yamamoto, H and Takeshita, A (1997). Adenovirus-mediated expression of the secreted form of basic fibroblast growth factor (FGF-2) induces cellular proliferation and angiogenesis in vivo. Arterioscler Thromb Vasc Biol 17: 2453-2460.
96. Giordano, FJ, Ping, P, McKiman, MD, Nozaki, S, DeMaria, AN, Dillmann, WH et al. (1996). Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 2: 534-539.
97. Lindahl, P, Johansson, BR, Leveen, P and Betsholtz, C (1997). Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277: 242-245.
98. Richardson, TP, Peters, MC, Ennett, AB and Mooney, DJ (2001). Polymeric system for dual growth factor delivery. Nat Biotechnol 19: 1029-1034.
99. Cao, R, Brakenhielm, E, Pawliuk, R, Wariaro, D, Post, MJ, Wahlberg, E et al. (2003). Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 9: 604-613.
100. Li, X, Tjwa, M, Moons, L, Fons, P, Noel, A, Ny, A et al. (2005). Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors. J Clin Invest 115: 118-127.
101. Ponten, A, Li, X, Thoren, P, Aase, K, Sjoblom, T, Ostman, A et al. (2003). Transgenic overexpression of platelet-derived growth factor-C in the mouse heart induces cardiac fibrosis, hypertrophy, and dilated cardiomyopathy. Am J Pathol 163: 673-682.
102. Aoki, M, Morishita, R, Taniyama, Y, Kida, I, Moriguchi, A, Matsumoto, K et al. (2000). Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: Up-regulation of essential transcription factor for angiogenesis, ets. Gene Ther 7: 417-427.
103. Thurston, G, Rudge, JS, Ioffe, E, Zhou, H, Ross, L, Croll, SD et al. (2000). Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6: 460-463.
104. Cho, CH, Kim, KE, Byun, J, Jang, HS, Kim, DK, Baluk, P et al. (2005). Long-term and sustained COMP-Ang1 induces long-lasting vascular enlargement and enhanced blood flow. Circ Res 97: 86-94.
105. Lobov, IB, Brooks, PC and Lang, RA (2002). Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 99: 11205-11210.
106. Patel, TH, Kimura, H, Weiss, CR, Semenza, GL and Hofmann, LV (2005). Constitutively active HIF-1alpha improves perfusion and arterial remodeling in an endovascular model of limb ischemia. Cardiavasc Res 68: 144-154.
107. Smith, RS Jr., Lin, KF, Agata, J, Chao, L and Chao, J (2002). Human endothelial nitric oxide synthase gene delivery promotes angiogenesis in a rat model of hindlimb ischemia. Arterioscler Thromb Vasc Biol 22: 1279-1285.
108. Ito, WD, Arras, M, Winkler, B, Scholz, D, Schaper, J and Schaper, W (1997). Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ Res 80: 829-837.
109. Zhong, J, Eliceiri, B, Stupack, D, Penta, K, Sakamoto, G, Quertermous, T et al. (2003). Neovascularization of ischemic tissues by gene delivery of the extracellular matrix protein Del-1. J. Clin Invest 112: 30-41.
110. Hiasa, K, Ishibashi, M, Ohtani, K, Inoue, S, Zhao, Q, Kitamoto, S et al. (2004). Gene transfer of stromal cell-derived factor-1α enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation 109: 2454-2461.
111. Tokunaga, N, Nagaya, N, Shirai, M, Tanaka, E, Ishibashi-Ueda, H, Harada-Shiba, M et al. (2004). Adrenomedullin gene transfer induces therapeutic angiogenesis in a rabbit model of chronic hind limb ischemia: Benefits of a novel nonviral vector, gelatin. Circulation 109: 526-531.
112. Nishiyama, K, Takaji, K, Kataoka, K, Kurihara, Y, Yoshimura, M, Kato, A et al. (2005). Id1 gene transfer confers angiogenic property on fully differentiated endothelial cells and contributes to therapeutic angiogenesis. Circulation 112: 2840-2850.
113. Kusano, KF, Pola, R, Murayama, T, Curry, C, Kawamoto, A, Iwakura, A et al. (2005). Sonic hedgehog myocardial gene therapy: Tissue repair through transient reconstitution of embryonic signaling. Nat Med 11: 1197-1204.
114. Wilson, BD, Ii, M, Park, KW, Suli, A, Sorensen, LK, Larrieu-Lahargue, F et al. (2006). Netrins promote developmental and therapeutic angiogenesis. Science 313: 640-644.
115. van Royen, N, Schirmer, SH, Atasever, B, Behrens, CY, Ubbink, D, Buschmann, EE et al. (2005). START Trial: A pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease. Circulation 112: 1040-1046.
116. Shyu, KG, Chang, H, Wang, BW and Kuan, P (2003). Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. Am J Med 114: 85-92.
117. Losordo, DW, Vale, PR, Symes, JF, Dunnington, CH, Esakof, DD, Maysky, M et al. (1998). Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF(165) as sole therapy for myocardial ischemia. Circulation 98: 2800-2804.
118. Vale, PR, Losordo, DW, Milliken, CE, Maysky, M, Esakof, DD, Symes, JF et al. (2000). Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 102: 965-974.
119. Sylven, C, Sarkar, N, Ruck, A, Drvota, V, Hassan, SY, Lind, B et al. (2001). Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A165 plasmid in patients with inoperable angina pectoris. Coron Artery Dis 12: 239-243.
120. Ripa, RS, Wang, Y, Jorgensen, E, Johnsen, HE, Hesse, B and Kastrup, J (2006). Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur Heart J 127: 1785-1792.
121. Reilly, JP, Grise, MA, Fortuin, FD, Vale, PR, Schaer, GL, Lopez, J et al. (2005). Long-term (2-year) clinical events following transthoracic intramyocardial gene transfer of VEGF-2 in no-option patients. J Interv Cardiol 18: 27-31.
122. Rajagopalan, S, Shah, M, Luciano, A, Crystal, R and Nabel, EG (2001). Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve. Circulation 104: 753-755.
123. Rajagopalan, S, Olin, J, Deitcher, S, Pieczek, A, Laird, J, Grossman, PM et al. (2007). Use of a constitutively active hypoxia-inducible factor-1 (α) transgene as a therapeutic strategy in no-option critical limb ischemia patients. Phase I dose-escalation experience. Circulation 115: 1234-1243.
124. Rajagopalan, S, Mohler, ER 3rd, Lederman, RJ, Mendelsohn, FO, Saucedo, JF, Goldman, CK et al. (2003). Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108: 1933-1938.
125. Laitinen, M, Hartikainen, J, Hiltunen, MO, Eränen, J, Kiviniemi, M, Närvänen, O et al. (2000). Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum Gene Ther 11: 263-270.
126. Grines, CL, Watkins, MW, Helmer, G, Penny, W, Brinker, J, Mannur, JD et al. (2002). Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105: 1291-1297.
127. Grines, CL, Watkins, MW, Mahmarian, JJ, Iskandrian, AE, Rade, JJ, Marrott, P et al. (2003). A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 42: 1339-1347.
128. Barbeau, G, Beatt, K, Betriu, A, Janssens, S, Martinez-Rios, M, Mautner, B et al. (2006). Adenoviral fibroblast growth factor-4 gene therapy in patients with stable angina. 12-month results of a double blind randomized multicenter trial. J Am Coll Cardiol 47 (Suppl 1): 305A.
129. Cardium Therapeutics (2006). Summary of generx clinical development. Cardium Therapeutics. .
130. ClinicalTrials.gov (2007). Angiogenesis in women with angina pectoris who are not candidates for revascularization (AWARE). ClinicalTrials.gov. .
131. Losordo, DW, Vale, PR, Hendel, RC, Milliken, CE, Fortuin, FD, Cummings, N et al. (2002). Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 105: 2012-2018.
132. Stewart, DJ, Hilton, JD, Arnold, JM, Gregoire, J, Rivard, A, Archer, SL et al. (2006). Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: A phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther 13: 1503-1511.
133. ClinicalTrials.gov (2006). Safety and efficacy study of Ad2/hypoxia inducible factor (HIF)-1a/VP16 gene transfer in patients with intermittent claudication. ClinicalTrials.gov. .
134. Powell, RJ, Dormandy, J, Simons, M, Morishita, R and Annex, BH (2004). Therapeutic angiogenesis for critical limb ischemia: Design of the hepatocyte growth factor therapeutic angiogenesis clinical trial. Vasc Med 9: 193-198.
135. Valentis (2006). Valentis announces results of VLTS 934 phase llb trial. Valentis. .
136. Nikol, S, Baumgartner, I, Van Belle, E, Diehm, C, Visona, A, Capogrossi, MC et al. (2006). Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Late breaking clinical trial. American College of Cardiology 55th Annual Scientific Session.
137. Henry, TD, Mendelsohn, F, Comerota, A, Pham, E, Grek, V, Coleman, M et al. (2006). Dose and regimen effects of intramuscular NV1FGF in patients with critical limb ischemia: A randomized, double-blind, placebo controlled study. Eur Heart J 27 (Suppl 1): 235.
138. ClinicaTrials.gov (2006). NOGA angiogenesis revascularization therapy: evaluation by radionuclide imaging - the northern trial. Clinicaltrials.gov. .
139. ClinicalTrials.gov (2006). A study to treat patients whose chronic angina symptoms are not relieved by medication and have an area of the heart that cannot be treated by standard therapies. ClinicalTrials.gov. .
140. Leppanen, O, Rutanen, J, Hiltunen, MO, Rissanen, TT, Turunen, MP, Sjoblom, T et al. (2004). Oral imatinib mesylate (STI571/gleevec) improves the efficacy of local intravascular vascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits. Circulation 109: 1140-1146.
141. Rutanen, J, Turunen, AM, Teittinen, M, Rissanen, TT, Heikura, T, Koponen, JK et al. (2005). Gene transfer using the mature form of VEGF-D reduces neointimal thickening through nitric oxide-dependent mechanism. Gene Ther 12: 980-987.
142. Khurana, R, Zhuang, Z, Bhardwaj, S, Murakami, M, De Muinck, E, Yla-Herttuala, S et al. (2004). Angiogenesis-dependent and independent phases of intimal hyperplasia. Circulation 110: 2436-2443.
143. Bhardwaj, S, Roy, H, Heikura, T and Yla-Herttuala, S (2005). VEGF-A, VEGF-D and VEGF-D(DeltaNDeltaC) induced intimal hyperplasia in carotid arteries. Eur J Clin Invest 35: 669-676.
144. Janssens, S, Flaherty, D, Nong, Z, Varenne, O, Van Pelt, N, Haustermans,C et al. (1998). Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation 97: 1274-1281.
145. Numaguchi, Y, Naruse, K, Harada, M, Osanai, H, Mokuno, S, Murase, K et al. (1999). Prostacyclin synthase gene transfer acccelerates reendothelialization and inhibits neointimal formation in rat carotid arteries after balloon injury. Arterioscler Thromb Vasc Biol 19 727-733.
146. Laukkanen, MO, Kivela, A, Rissanen, T, Rutanen, J, Karkkainen, MK, Leppanen, O et al. (2002). Adenovirus-mediated extracellular superoxide dismutase gene therapy reduces neointima formation in balloon-denuded rabbit aorta. Circulation 106: 1999-2003.
147. Kutryk, MJ, Foley, DP, van den Brand, M, Hamburger, JN, van der Giessen, WJ, deFeyter, PJ et al. (2002). Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: Results of the randomized investigation by the thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J Am Coll Cardiol 39: 281-287.
148. Chiu-Pinheiro, CK, O'Brien, T, Katusic, ZS, Bonilla, LF, Hamner, CE and Schaff, HV (2002). Gene transfer to coronary artery bypass conduits. Ann Thorac Surg 74: 1161-1166.
149. Fuster, V, Charlton, P and Boyd, A (2001). Clinical protocol. A phase IIb, randomized, multicenter, double-blind study of the efficacy and safety of Trinam (EG004) in stenosis prevention at the graft-vein anastamosis site in dialysis patients. Hum Gene Ther 12: 2025-2027.
150. Luo, Z, Akita, GY, Date, T, Treleaven, C, Vincent KA, Woodcock, D et al. (2005). Adenovirus-mediated expression of beta-adrenergic receptor kinase C-terminus reduces intimal hyperplasia and luminal stenosis of arteriovenous polytetrafluoroethylene grafts in pigs. Circulation 111: 1679-1684.
151. Kibbe, MR, Tzeng, E, Gleixner, SL, Watkins, SC, Kovesdi, I, Lizonova, A et al. (2001). Adenovirus-mediated gene transfer of human inducible nitric oxide synthase in porcine vein grafts inhibits intimal hyperplasia. J Vasc Surg 34: 156-165.
152. Puhakka, HL, Turunen, P, Rutanen, J, Hiltunen, MO, Turunen, MP and Yla-Herttuala, S (2005). Tissue inhibitor of metalloproteinase 1 adenaviral gene therapy alone is equally effective in reducing restenosis as combination gene therapy in a rabbit restenosis model. J Vasc Res 42: 361-367.
153. Yla-Herttuala, S, Markkanen, JE and Rissanen, TT (2004). Gene therapy for ischemic cardiovascular diseases: Some lessons learned from the first clinical trials. Trends Cardiovasc Med 14: 295-300.
154. Ratner, M (2004). Genentech discloses safety concerns over Avastin. Nat Biotechnol 22: 1198.
155. Lemstrom, KB, Krebs, R, Nykanen, AI, Tikkanen, JM, Sihvola, RK, Aaltola, EM et al. (2002). Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. Circulation 105: 2524-2530.
156. Ryu, JK, Cho, CH, Shin, HY, Song, SU, Oh, SM, Lee, M et al. (2006). Combined angiopoietin-1 and vascular endothelial growth factor gene transfer restores cavernous angiogenesis and erectile function in a rat model of hypercholesterolemia. Mol Ther 13: 705-715.
157. Nykanen, AI, Krebs, R, Saaristo, A, Turunen, P, Alitalo, K, Yla-Herttuala, S et al. (2003). Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation 107: 1308-1314.
158. Nykanen, AI, Pajusola, K, Krebs, R, Keranen, MA, Raisky, O, Koskinen, PK et al. (2006). Common protective and diverse smooth muscle cell effects of AAV-mediated angiopoietin-1 and -2 expression in rat cardiac allograft vasculopathy. Circ Res 98: 1373-1380.
159. Chen, SJ, Wilson, JM and Muller, DW (1994). Adenovirus-mediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts. Circulation 89: 1922-1928.
160. Ali, ZA Bursill, CA, Hu, Y, Choudhury, RP, Xu, Q, Greaves, DR et al. (2005). Gene transfer of a broad spectrum CC-chemokine inhibitor reduces vein graft atherosclerosis in apolipoprotein E-knockout mice. Circulation 112 (Suppl 9): 1235-1241.
161. Schepers, A, Eefting, D, Bonta, PI, Grimbergen, JM, de Vries, MR, van Weel, V et al. (2006). Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. Arterioscler Thromb Vasc Biol 26: 2063-2069.
162. Eslami, MH, Gangadharan, SP, Sui, X, Rhynhart, KK, Snyder, RO and Conte, MS (2000). Gene delivery to in situ veins: Differential effects of adenovirus and adeno-associated viral vectors. J Vasc Surg 31 1149-1159.
163. Mann, MJ, Whittemore, AD, Donaldson, MC, Belkin, M, Conte, MS, Polak JF et al. (1999). Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial. Lancet 354: 1493-1498.
164. Banno, H, Takei, Y, Muramatsu, T, Komori, K and Kadomatsu, K (2006). Controlled release of small interfering RNA targeting midkine attenuates intimal hyperplasia in vein grafts. J Vasc Surg 44: 633-641.
165. Grossman, M, Rader, DJ, Muller, DW, Kolansky, DM, Kozarsky, K, Clark BJ 3rd et al. (1995). A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1: 1148-1154.
166. Lebherz, C, Gao, G, Louboutin, JP, Millar, J, Rader, D and Wilson, JM (2004). Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. J Gene Med 6: 663-672.
167. Jalkanen, J, Leppanen, P, Pajusola, K, Narvanen, O, Mahonen, A, Vahakangas, E et al. (2003). Adeno-associated virus-mediated gene transfer of a secreted decoy human macrophage scavenger receptor reduces atherosclerotic lesion formation in LDL receptor knockout mice. Mol Ther 8: 903-910.
168. Kitajima, K, Marchadier, DH, Miller, GC, Gao, GP, Wilson, JM and Rader, DJ (2006). Complete prevention of atherosclerosis in apoE-deficient mice by hepatic human apoE gene transfer with adeno-associated virus serotypes 7 and 8. Arterioscler Thromb Vasc Biol 26: 1852-1857.
169. Cichon, G, Willnow, T, Herwig, S, Uckert, W, Loser, P, Schmidt HH et al. (2004). Non-physiological overexpression of the low density lipoprotein receptor (LDLr) gene in the liver induces pathological intracellular lipid and cholesterol storage. J Gene Med 6: 166-175.
170. Kastelein, JJ, Wedel, MK, Baker, BF, Su, J, Bradley, JD, Yu, RZ et al. (2006). Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114: 1729-1735.
171. Zoldhelyi, P, McNatt, J, Xu, XM, Loose-Mitchell, D, Meidell, RS, Clubb, FJ Jr. et al. (1996). Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene. Circulation 93: 10-17.
172. Waugh, JM, Kattash, M, Li, J, Yuksel, E, Kuo, MD, Lussier, M et al. (1999). Gene therapy to promote thromboresistance: Local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model. Proc Natl Acad Sci USA 96: 1065-1070.
173. Waugh, JM, Yuksel, E, Li, J, Kuo, MD, Kattash, M, Saxena, R et al. (1999). Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model. Circ Res 84: 84-92.
174. Zoldhelyi, P, McNatt, J, Shelat HS, Yamamoto, Y, Chen, ZQ and Willerson, JT (2000). Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor. Circulation 101: 289-295.
175. Ohno, N, Itoh, H, Ikeda, T, Ueyama, K, Yamahara, K, Doi, K et al. (2002). Accelerated reendothelialization with suppressed thrombogenic: property and neointimal hyperplasia of rabbit jugular vein grafts by adenovirus-mediated gene transfer of C-type natriuretic peptide. Circulation 105: 1623-1626.
176. Furukoji, E, Matsumoto, M, Yamashita, A, Yagi, H, Sakurai, Y, Marutsuka, K et al. (2005). Adenovirus-mediated transfer of human placental ectonucleoside triphosphate diphosphohydrolase to vascular smooth muscle cells suppresses platelet aggregation in vitro and arterial thrombus formation in vivo. Circulation 111: 808-815.
177. Raizada, MK and Der Sarkissian, S (2006). Potential of gene therapy strategy for the treatment of hypertension. Hypertension 47: 6-9.
178. Miller, WH, Brosnan, MJ, Graham, D, Nicol, CG, Morecroft I, Channon, KM et al. (2005). Targeting endothelial cells with adenovirus expressing nitric oxide synthase prevents elevation of blood pressure in stroke-prone spontaneously hypertensive rats. Mol Ther 12: 321-327.
179. Wang, HW, Katovich, MJ, Gelband, CH, Reaves, PY, Phillips, MI and Raizada, MK (1999). Sustained inhibition of angiotensin I-converting enzyme (ACE) expression and long-term antihypertensive action by virally mediated delivery of ACE antisense cDNA. Circ Res 85: 614-622.
180. Wang, T, Li, H, Zhao, C, Chen, C, Li, J, Chao, J et al. (2004). Recombinant adeno-associated virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries. Gene Ther 11: 1342-1350.
181. Schillinger, KJ, Tsai, SY, Taffet, GE, Reddy, AK, Marian, AJ, Entman, ML et al. (2005). Regulatable atrial natriuretic peptide gene therapy for hypertension. Proc Natl Acad Sci USA 102: 13789-13794.
182. Nagaya, N, Yokoyama, C, Kyotani, S, Shimonishi, M, Morishita, R, Uematsu, M et al. (2000). Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats. Circulation 102: 2005-2010.
183. McMurtry, MS, Archer, SL, Altieri, DC, Bonnet, S, Haromy, A, Harry, G et al. (2005). Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 115: 1479-1491.
184. Leotta, E, Patejunas, G, Murphy, G, Szokol, J, McGregor, L, Carbray, J et al. (2002). Gene therapy with adenovirus-mediated myocardial transfer of vascular endothelial growth factor 121 improves cardiac performance in a pacing model of congestive heart failure. J Thorac Cardiovasc Surg 123: 1101-1113.
185. Miyamoto, MI, del Monte, F, Schmidt U, DiSalvo, TS, Kang, ZB, Matsui, T et al. (2000). Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA 97: 793-798.
186. Szatkowski, ML, Westfall, MV, Gomez, CA, Wahr, PA, Michele, DE, DelloRusso, C et al. (2001). In vivo acceleration of heart relaxation performance by parvalbumin gene delivery. J Clin Invest 107: 191-198.
187. Most, P, Pleger, ST, Volkers, M, Heidt, B, Boerries, M, Weichenhan, D et al. (2004). Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest 114: 1550-1563.
188. Hoshijima, M, Ikeda, Y, Iwanaga, Y, Minamisawa, S, Date, MO, Gu, Y et al. (2002). Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 8: 864-871.
189. Maurice, JP, Hata, JA, Shah, AS, White, DC, McDonald, PH, Dolber, PC et al. (1999). Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-adrenergic receptor gene delivery. J Clin Invest 104: 21-29.
190. Hambleton, M, Hahn, H, Pleger, ST, Kuhn, MC, Klevitsky, R, Carr, AN et al. (2006). Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation 114: 574-582.
191. Tenhunen, O, Soini, Y, Ilves, M, Rysa, J, Tuukkanen, J, Serpi, R et al. (2006). p38 Kinase rescues failing myocardium after myocardial infarction: Evidence for angiogenic and anti-apoptotic mechanisms. FASEB J 20: 1907-1909.
192. Chatterjee, S, Stewart AS, Bish, LT, Jayasankar, V, Kim, EM, Pirolli, T et al. (2002). Viral gene transfer of the antiapoptotic factor Bcl-2 protects against chronic postischemic heart failure. Circulation 106 (Suppl 1): 1212-4217.
193. Woo, YJ, Panlilio, CM, Cheng, RK, Liao, GP, Atluri, P, Hsu, VM et al. (2006). Therapeutic delivery of cyclin A2 induces myocardial regeneration and enhances cardiac function in ischemic heart failure. Circulation 114 (Suppl 1): 1206-1213.
194. Laugwitz, KL, Moretti, A, Weig, HJ, Gillitzer, A, Pinkernell, K, Ott, T et al. (2001). Blocking caspase-activated apoptosis improves contractility in failing myocardium. Hum Gene Ther 12: 2051-2063.
195. Lai, NC, Roth, DM, Gao, MH, Tang, T, Dalton, N, Lai, YY et al. (2004). Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure. Circulation 110: 330-336.
196. Melo, LG, Agrawal, R, Zhang, L, Rezvani, M, Mangi, AA, Ehsan, A et al. (2002). Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation 105: 602-607.
197. Rosen, MR, Brink, PR, Cohen, IS and Robinson, RB (2004). Genes, stem cells and biological pacemakers. Cardiavasc Res 64: 12-23.
198. Kashiwakura, Y, Cho, HC, Barth, AS, Azene, E and Marban, E (2006). Gene transfer of a synthetic pacemaker channel into the heart: A novel strategy for biological pacing. Circulation 114: 1682-1686.
199. Tse, HF, Xue, T, Lau, CP, Siu, CW, Wang, K, Zhang, QY et al. (2006). Bioartificial sinus node constructed via in vivo gene transfer of an engineered pacemaker HCN Channel reduces the dependence on electronic pacemaker in a sick-sinus syndrome model. Circulation 114: 1000-1011.
200. Immonen, A, Vapalahti, M, Tyynela, K, Hurskainen, H, Sandmair, A, Vanninen, R et al. (2004). AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomised, controlled study. Mol Ther 10: 967-972.